Athira Pharma/ATHA

$2.55

-0.39%
-
1D1W1MYTD1YMAX

About Athira Pharma

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

Ticker

ATHA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Litton

Employees

65

Headquarters

Bothell, United States

Athira Pharma Metrics

BasicAdvanced
$101M
Market cap
-
P/E ratio
-$3.05
EPS
2.93
Beta
-
Dividend rate
$101M
2.93293
$4.30
$1.33
315K
5.025
-63.45%
-73.11%
-72.51%
0.948
0.948
-12.51%

What the Analysts think about Athira Pharma

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
185.49% upside
High $19.00
Low $2.65
$2.55
Current price
$7.28
Average price target

Athira Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$26M
-3.31%
Profit margin
0%
NaN%

Athira Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.71%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.78
-$0.87
-$0.71
-$0.69
-
Expected
-$0.78
-$0.81
-$0.96
-$0.79
-$0.73
Surprise
-0.4%
6.88%
-26.02%
-12.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Athira Pharma stock?

Athira Pharma (ATHA) has a market cap of $101M as of May 29, 2024.

What is the P/E ratio for Athira Pharma stock?

The price to earnings (P/E) ratio for Athira Pharma (ATHA) stock is 0 as of May 29, 2024.

Does Athira Pharma stock pay dividends?

No, Athira Pharma (ATHA) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next Athira Pharma dividend payment date?

Athira Pharma (ATHA) stock does not pay dividends to its shareholders.

What is the beta indicator for Athira Pharma?

Athira Pharma (ATHA) has a beta rating of 2.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Athira Pharma stock price target?

The target price for Athira Pharma (ATHA) stock is $7.28, which is 185.49% above the current price of $2.55. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Athira Pharma stock

Buy or sell Athira Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing